Skip to main content

Scleroderma/Raynauds

Roundup RHeum ACR
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Rheumatology Round-Up with Drs. Kavanaugh & Cush

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.

physical therapy
Systemic sclerosis (SSc) is a chronic fibrosing disease currently with no available cure. Just as pharmacologic treatment is important to control the disease or delay its progression, non-…
RT @TheLancetRheum: Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffus

The Lancet Rheumatology TheLancetRheum

3 weeks 5 days ago
Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20 Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy
RT @ejdein1: Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mR

Eric Dein ejdein1

3 weeks 5 days ago
Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/qpvLFsAe0x
Using National Inpatient Sample (NIS) claims, SSc pts hospitalized with acute MI (AMI) had a higher unadjusted inpatient

Dr. John Cush RheumNow

3 weeks 6 days ago
Using National Inpatient Sample (NIS) claims, SSc pts hospitalized with acute MI (AMI) had a higher unadjusted inpatient mortality rate (9.17% vs. 4.68%; p=0.001)( (aOR=2.02) #ACR20 Abstr#1390 https://t.co/qWUMkJR40d
RT @drdavidliew: Nintedanib in rheum ILD (RA/SSc/CTD)
I appreciate the volumes might not seem like much, but:
- in first

David Liew drdavidliew

3 weeks 6 days ago
Nintedanib in rheum ILD (RA/SSc/CTD) I appreciate the volumes might not seem like much, but: - in first 1y Rx 20% more are spared a FVC decline>10% - biggest diff in UIP-like pattern With the right patient selection, nintedanib does have its place! #ACR20 ABST1048/1049 @RheumNow https://t.co/jGZdR84bBU
RT @doctorRBC: Racial disparity in SSc-ILD pts treated with MMF?
1️⃣Early initiation of MMF significantly slowed ⬇

Robert B Chao, MD doctorRBC

4 weeks ago
Racial disparity in SSc-ILD pts treated with MMF? 1️⃣Early initiation of MMF significantly slowed ⬇️ of FVC% 2️⃣No difference in MMF efficacy between African-Americans and non-AA 3️⃣AA had baseline lower FVC% @RheumNow #ACR20 Abs0929 https://t.co/rtsbe7OCvA
RT @Janetbirdope: Interesting data re HCQ decreasing new PAH in Early SSc #scleroderma Not sure I believe it. Confoundin

Janet Pope Janetbirdope

4 weeks ago
Interesting data re HCQ decreasing new PAH in Early SSc #scleroderma Not sure I believe it. Confounding, diff subsets get #hydroxycholoroquine due to inflammatory arthritis etc. Maybe a big pragmatic RCT is warranted as PAH is lethal @RheumNow @CRASCRRheum #ACR20 abstr#925 https://t.co/Al81sMGgxI
RT @doctorRBC: Hydroxychloroquine may reduce rate of progression of systemic sclerosis associated pulmonary hypertension

Robert B Chao, MD doctorRBC

4 weeks ago
Hydroxychloroquine may reduce rate of progression of systemic sclerosis associated pulmonary hypertension when initiated early (<18 months). Prospective, observational study. @RheumNow #ACR2020 Abs#0925 https://t.co/nj0mNAY5Pe
×